S. Bahadoram, M. Mahmoudian-sani, B. Keikhaei, M. Bahadoram, Amar Helalinasab, E. Akade
{"title":"秋水仙碱;炎症小体抑制剂和重症covid - 19的潜在治疗方法?","authors":"S. Bahadoram, M. Mahmoudian-sani, B. Keikhaei, M. Bahadoram, Amar Helalinasab, E. Akade","doi":"10.34172/jre.2022.19065","DOIUrl":null,"url":null,"abstract":"policy/practice/research/medical education Inflammatory reactions are among the most adverse complications of COVID-19 patients. These reactions occur generally via inflammasomes. Inflammasomes are regulated by some proteins such as NLRP3. Colchicine is well-known drug which bars inflammasome formation by inhibiting NLRP3. In presented article we propose studying efficacy, adverse effects, and exact mechanism of action of colchicine in COVID-19 patients.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"30 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Colchicine; An inflammasome inhibitor and a potential therapy in severe COVID19?\",\"authors\":\"S. Bahadoram, M. Mahmoudian-sani, B. Keikhaei, M. Bahadoram, Amar Helalinasab, E. Akade\",\"doi\":\"10.34172/jre.2022.19065\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"policy/practice/research/medical education Inflammatory reactions are among the most adverse complications of COVID-19 patients. These reactions occur generally via inflammasomes. Inflammasomes are regulated by some proteins such as NLRP3. Colchicine is well-known drug which bars inflammasome formation by inhibiting NLRP3. In presented article we propose studying efficacy, adverse effects, and exact mechanism of action of colchicine in COVID-19 patients.\",\"PeriodicalId\":16964,\"journal\":{\"name\":\"Journal of Renal Endocrinology\",\"volume\":\"30 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Renal Endocrinology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34172/jre.2022.19065\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Renal Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jre.2022.19065","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Colchicine; An inflammasome inhibitor and a potential therapy in severe COVID19?
policy/practice/research/medical education Inflammatory reactions are among the most adverse complications of COVID-19 patients. These reactions occur generally via inflammasomes. Inflammasomes are regulated by some proteins such as NLRP3. Colchicine is well-known drug which bars inflammasome formation by inhibiting NLRP3. In presented article we propose studying efficacy, adverse effects, and exact mechanism of action of colchicine in COVID-19 patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
